Amendments to the Claims:

1-20 (cancelled)

21. (currently amended) A compound of formula



wherein

A is –N=CR-CR=CR-; -CR=N-CR=CR-; -CR=CR-N=CR-; or -CR=CR-CR=N-~~=N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=~~;

$\mathbf{R_1}$ is selected from the group consisting of:

-hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

$-NO_2$;

-OH; and

-SH; and

$-C_{1-20}$ alkyl-NR_3-Q-X-R_4 or $-C_{2-20}$ alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or $-SO_2-$; **X** is a bond, -O- or $-NR_3-$ and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or $-C_{1-20}$ alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

$-NO_2$;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

22. (currently amended) A compound of formula



wherein

$\mathbf{R_1}$ is selected from the group consisting of:

-hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl-O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

23. (currently amended) A compound of formula



8

wherein

$\mathbf{R_1}$ is selected from the group consisting of:

-hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_2 is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl-O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

24. (currently amended) A compound of formula



wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;

$\mathbf{R_7}$ is OH, halogen, or NHR_1,

$\mathbf{R_1}$ is selected from the group consisting of:

-hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$-C_{1-20} alkyl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_8 is H, NO_2 or NH_2;

each **R_3** is independently selected from the group consisting of hydrogen and C_{1-10}alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

25. (currently amended) A compound of formula



wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl; and

$\mathbf{R_9}$ is H or C_{1-10} alkyl.

26 (currently amended) A compound of formula



wherein

$\mathbf{R_1}$ is selected from the group consisting of:

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl;

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-$S(O)_{0-2}$-C_{1-20} alkyl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-$N(R_3)_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl;

-O-(C_{1-20} alkyl)$_{0-1}$-aryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-$S(O)_{0-2}$-C_{1-20} alkyl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-aryl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-$S(O)_{0-2}$–(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-$N(R_3)_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

$-NO_2$;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl;

each **R** is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl; and

$\mathbf{R_{10}}$ is $-NO_2$ or NH_2;

or a pharmaceutically acceptable salt thereof.

REMARKS

Claims 1-20 are cancelled.

Claims 21-26 are amended. The basis for amending Claim 21 is the requirement for proper valence for the carbon atoms common to the A ring and the adjoining ring. Claim 22 is amended to correct a typographical error in the spelling of the word "consisting" in the definition of R_1. Claims 23 and 26 are amended to insert the word "and" for a proper R_1 Markush group. Claim 24 is amended to include the definition for R_3, basis for which can be found, for example, at page 23, lines 11-12 and page 6, lines 4-5. Claim 25 is amended to include the definition for R, basis for which can be found, for example, at page 24, line 6, and page 6, lines 6-7.

Claims 21-26 are pending.

This is a divisional directed to groups I-V in the restriction requirement applied to parent Application No. 10/406,181. No new matter has been added.